Target
tumor-infiltrating lymphocytes (TILs)
5 abstracts
Abstract
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.Org: Iovance Biotherapeutics, H. Lee Moffitt Cancer Center and Research Institute, UPMC Hillman Cancer Center, The Royal Marsden Hospital NHS Foundation Trust, Perlmutter Cancer Center, NYU Langone Health,
Abstract
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.Org: Iovance Biotherapeutics, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
Tolerability and response of palliative radiotherapy in patients receiving tumor-infiltrating lymphocyte therapy.Org: School of Medicine, Zhejiang University, Hangzhou, China, University of Louisville, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Brown Cancer Center, Tufts University Medical Center,
Abstract
Prognostic value of systemic inflammatory response in early-stage triple-negative breast cancer.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Institute of Oncology Ljubljana,